Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
CA3113037A1
Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis
EP3771718A1
Process for preparing the crystalline form ii of sotagliflozin
EP3771480A1
Continuous process for preparing the crystalline form ii of sotagliflozin
EP3769767A1
Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
TW201620911A
Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use
WO2015035167A1
IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
TW201542550A
Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
WO2014082034A1
Methods for treating irritable bowel syndrome
NZ707859A
Inhibitors of sodium glucose cotransporter 1
AU2013213761A1
(7h-pyrrolo [2, 3-d] pyrimidin-4-yl) - piperazines as kinase inhibitors for the treatment of cancer and inflammation
AU2013206276A1
Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
WO2013148978A1
Methods and compositions for the treatment of necrotizing enterocolitis
AU2013230066A1
Inhibition of adaptor associated kinase 1 for the treatment of pain
SG11201405561RA
PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
KR20140138865A
Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
NZ717137A
Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
CA2837084A1
4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use
AU2012225805A1
MST1 kinase inhibitors and methods of their use
TW201309345A
Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
